Artificial intelligence has the potential to transform healthcare, and some of the most exciting opportunities are being pursued by innovators to solve problems in drug development and medicine. Join us during the J.P. Morgan Healthcare Conference on the evening of January 15th, 2020, and meet leaders from top startups in the space—you’ll have the opportunity to hear first-hand about how they’re using AI to develop novel molecules, improve high-throughput screening, optimize clinical trials, and enable unprecedented advances in precision medicine.
Participate and engage with founders, innovators, and hundreds of MIT alumni and their guests during the AI in Drug Discovery and Medicine startup showcase at First Republic Bank, One Front Street and 111 Pine Street, San Francisco.
This will be our third year hosting an event during JPM; companies joining us this year include:
DNAnexus, Atomwise, Qulab, doc.ai, Haystack Sciences, Gordian Biotechnology, Genialis, Plex Research, Galileo Biosystems, Multiply Labs, Coral Genomics, noul, Fountain Therapeutics, Kali Care, Unlearn.AI, Peach IntelliHealth,TeselaGen, Engine Biosciences, and Arbor Biotechnologies.
COMPANY EXHIBIT TABLES - If you are interested in joining us to showcase your company in 2020, contact us soon, before the remaining slots are filled.
#MITCNC #MIT #AI #JPMorgan #Drug Discovery #Precision Medicine #Clinical Trials #High Throughput Screening
DNAnexus has built the world’s most secure, trusted cloud platform and global network for scientific collaboration and accelerated discovery.
Atomwise is the leader in AI drug discovery and partners with academia, biotech, and pharma on hundreds of small molecule programs.
Qulab pioneers turning drug discovery into a design process by integrating AI molecule designer and synthesis planner with accurate bio-simulators.
Haystack’s nDexer™ gives 100x better DEL screening data, and combining it with powerful ML, radically informs and speeds drug discovery.
Gordian has invented a technology platform for screening hundreds of therapeutics in individual animals, to find cures for diseases of aging.
Genialis tackles diseases of unmet need with in silico precision medicine, blending compbio & AI for translational & clinical discovery.
Galileo combines metabolomics with large scale computation and proprietary algorithms to study chemical signaling between humans and their microbiome.
Advanced robotics that enables the manufacturing of personalized pharmaceutical products.
Coral is building the largest database to predict variation in drug response
Noul’s miLab platform combines AI with automated sample prep to enable highly accurate clinical testing for diagnostics and research.
Fountain Therapeutics applies AI and computer vision to novel cellular models of aging to discover and develop age-directed therapeutics.
Powered by objective patient-data, Kali's analytics platform sifts through millions of data points to accelerate clinical trials and improve patient outcomes.
Unlearn.AI creates AI-generated Digital Twins to populate Intelligent Control Arms in clinical trials, improving trial speed and statistical power.
5 MIT scientists started Peach to create best-in-class AI that pharma, medtech, hospitals can use to improve efficacy and patient outcomes
TeselaGen is a data driven discovery platform that enables the design, synthesis, data collection & optimization of life saving therapeutics
Engine empowers drug discovery by integrating machine learning and high-throughput biological experimentation to decipher complex biology
Arbor Biotechnologies is developing new CRISPR gene editing technologies with therapeutic applications using its next-generation big data platform
Plex Research has built the world’s first AI drug discovery platform powered by search engine algorithms.
Privacy-preserving A.I. and poly-omics, real-world data pipeline to optimize engagement, accelerate insights and transform approaches to care.
Note: If you are interested in joining us to showcase your company, contact us ASAP--only a few slots remain. Exhibitor pricing will also go up after December 15th, 2019
New to the MIT Club of Northern California?
Enjoy access to members-only events, early access to popular events, member pricing, vote for board members, and other members-only benefits.
About the MIT Club of Northern California (MITCNC) :
The MITCNC is a non-profit. Our mission is to exchange ideas with our community, and connect MIT alumni in the Bay Area--where there are 14000 alumni, the largest presence outside of Boston. To date, the MITCNC has organized over 60 events per year, and last year alone, over 4000 alumni attended our events. Our events generally follow one of three main tracks: healthcare & life sciences, energy & environment, or technology. For more info on upcoming events, see the listing here. Our events are open, and we welcome everyone in the community!
Our January 15, 2020 event, "AI in Drug Discovery and Medicine", promises to be well-attended; MIT alumni from all over the world are flying in to attend the JP Morgan Healthcare conference at the same time. "AI in Healthcare" is part of our monthly healthcare & life sciences event series, ongoing since 2017, when it was kicked-off at our "Future of AI conference". Speakers at the conference/event series have included senior executives from Google, Amazon, and Microsoft, as well as high-growth startup founders and venture investors.
Special thanks to our venue sponsor, First Republic Bank for hosting us!